Regeneron and Sanofi have restructured their global immuno-oncology discovery and development agreement for new immuno-oncology cancer treatments, with Sanofi set to pay $462 million to end the collaboration early.
News
José Baselga new AstraZeneca head of R&D Oncology
AstraZeneca has appointed “world-renowned oncology scientist” José Baselga as the new head of its research and development unit for Oncology.
Eli Lilly to buy Loxo Oncology for $8 billion
Eli Lilly has announced its intention to buy pioneering cancer treatment development company Loxo Oncology in a deal worth approximately $8 billion.
Takeda completes Shire acquisition
Takeda has completed its £46-billion acquisition of Shire, a deal that took just eight months to see through from announcement to close.
Daiichi & Esperion agreement for Bempedoic Acid
Daiichi Sankyo Europe has entered into a European licensing agreement with Esperion for bempedoic acid, and the bempedoic acid/ezetimibe combination tablet.
NHS Long Term Plan to save up to 500,000 lives
Long-awaited details of the NHS Long Term Plan, which is to be funded by a government investment of £20.5 billion a year in real terms by 2023/24 – have now been unveiled, with the promise of saving almost half a million more lives.
Janssen files Stelara in Europe for ulcerative colitis
Janssen has submitted an application to the European Medicines Agency (EMA) seeking to expand the approval of Stelara to include the treatment of adults with moderately to severely active ulcerative colitis (UC).
Green light for Amryt’s epidermolysis bullosa study
An Independent Data Monitoring Committee (IDCM) has recommended that Amryt’s pivotal Phase III EASE trial for AP101 – a potential treatment for Epidermolysis Bullosa (EB) – should continue, raising hopes for a new therapy for the condition.
UK surge in cell and gene therapy trials
A surge in cell and gene therapy trials – an increase of 37% since 2017 – highlights the UK’s leading position as a developmental hub in the sector, says the Cell and Gene Therapy Catapult.
Clinical trial to develop cancer diagnosing breath test
Cancer Research UK has announced that researchers have launched a clinical trial to develop a breath test that could help to find cancer early, when treatment is more likely to be effective.
Bristol-Myers Squibb to buy Celgene
Bristol-Myers Squibb has unveiled its intent to acquire Celgene in a deal worth $74 billion, in order to “create a premier innovative biopharma company”.
NICE approves Xeljanz for Ulcerative Colitis
The National Institute for Health and Care Excellence (NICE) has approved Pfizer’s Xeljanz for adults with moderate to severe active ulcerative colitis.
Takeda to evaluate Crescendo Biologics’ Humabodies
Crescendo Biologics has announced that Takeda is planning to evaluate the application of its recently licensed Humabodies, for the development of novel CAR-T therapeutics.
NHS winter figures encouraging ahead of ‘toughest days’
The NHS Confederation has said that the latest NHS winter figures are encouraging, but that the ‘toughest days may well come later’.
MHRA responds to consultation on Brexit no-deal proposals
In advance of the UK leaving the European Union on 29 March 2019, the Medicines and Healthcare products Regulatory Agency (MHRA) has released a statement detailing its preparations for the event of a no-deal Brexit scenario.
